Huyabio International, Llc.
Clinical trials sponsored by Huyabio International, Llc., explained in plain language.
-
New pill targets tough cancers: early trial begins
Disease control OngoingThis early-phase study tests an experimental oral drug, HBI-2376, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific KRAS or EGFR gene mutations. The main goal is to find the safest dose and check for side effects. About 42 participan…
Phase: PHASE1 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New drug targets tough cancers with KRAS mutation
Disease control OngoingThis early-stage study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves through the body. About 44 adult…
Phase: PHASE1 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Apr 29, 2026 15:00 UTC